Literature DB >> 27398145

MicroRNA-154 inhibits growth and invasion of breast cancer cells through targeting E2F5.

Hui Xu1, Dan Fei2, Shan Zong1, Zhimin Fan1.   

Abstract

Accumulating evidence suggested that microRNA-154 (miR-154) might play important roles in the development of various cancer types. However, the role of miR-154 in breast cancer progression remains largely unknown. Here, miR-154 expression level was measured via quantitative real-time RT-PCR (qRT-PCR) in 36 pairs of human breast cancer tissues and adjacent normal breast tissues and in a panel of human breast cancer cell lines. Cell proliferation, cycle, migration, and invasion were assessed by CCK8 assay, flow cytometer assay, wound healing assay and transwell invasion assay, respectively. Luciferase reporter assay and Western blot was used to verify E2F transcription factor 5 protein (E2F5) as a novel target gene of miR-154. Our results showed that miR-154 was frequently downregulated in breast cancer tissues and cell lines. Overexpression of miR-154 in MCF-7 cells significantly inhibited cell proliferation, migration, and invasion, and increased cell arrest at G0/G1 stage in vitro. E2F5 was identified as a target of miR-154, and its expression was inversely correlated with miR-154 expression in clinical breast cancer tissues. In addition, downregulation of E2F5 in MCF7 cells had similar effect on cell proliferation, cycle, migration and invasion by miR-154 induced. These findings indicate that miR-154 acts as a tumor suppressor by targeting E2F5, suggesting miR-154 as a potential therapeutic target for the treatment of breast cancer.

Entities:  

Keywords:  Breast cancer; E2F5; invasion; migration; proliferation

Year:  2016        PMID: 27398145      PMCID: PMC4931156     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  30 in total

1.  miR-154 suppresses non-small cell lung cancer growth in vitro and in vivo.

Authors:  Xingyu Lin; Zhiguang Yang; Peng Zhang; Guoguang Shao
Journal:  Oncol Rep       Date:  2015-04-02       Impact factor: 3.906

2.  In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.

Authors:  Erming Tian; Jeffrey R Sawyer; Christoph J Heuck; Qing Zhang; Frits van Rhee; Bart Barlogie; Joshua Epstein
Journal:  Genes Chromosomes Cancer       Date:  2014-03-17       Impact factor: 5.006

3.  Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).

Authors:  Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman
Journal:  Lancet       Date:  2014-11-26       Impact factor: 79.321

4.  E2F5 as an independent prognostic factor in esophageal squamous cell carcinoma.

Authors:  Takeshi Ishimoto; Atsushi Shiozaki; Daisuke Ichikawa; Hitoshi Fujiwara; Hirotaka Konishi; Shuhei Komatsu; Takeshi Kubota; Kazuma Okamoto; Shingo Nakashima; Hiroki Shimizu; Yoshito Nako; Mitsuo Kishimoto; Eigo Otsuji
Journal:  Anticancer Res       Date:  2013-12       Impact factor: 2.480

5.  Mammalian microRNAs predominantly act to decrease target mRNA levels.

Authors:  Huili Guo; Nicholas T Ingolia; Jonathan S Weissman; David P Bartel
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

6.  A novel factor distinct from E2F mediates C-MYC promoter activation through its E2F element during exit from quiescence.

Authors:  Josué Alvaro-Blanco; Lorena Martínez-Gac; Esther Calonge; María Rodríguez-Martínez; Irene Molina-Privado; Juan M Redondo; José Alcamí; Erik K Flemington; Miguel R Campanero
Journal:  Carcinogenesis       Date:  2009-01-06       Impact factor: 4.944

7.  A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma.

Authors:  Ernest Nadal; Jinjie Zhong; Jules Lin; Rishindra M Reddy; Nithya Ramnath; Mark B Orringer; Andrew C Chang; David G Beer; Guoan Chen
Journal:  Clin Cancer Res       Date:  2014-05-15       Impact factor: 12.531

8.  miR-154 suppresses colorectal cancer cell growth and motility by targeting TLR2.

Authors:  Chaoguang Xin; Hao Zhang; Zanchao Liu
Journal:  Mol Cell Biochem       Date:  2013-11-16       Impact factor: 3.396

Review 9.  miRNAs in human cancer.

Authors:  Thalia A Farazi; Jessica I Spitzer; Pavel Morozov; Thomas Tuschl
Journal:  J Pathol       Date:  2010-11-18       Impact factor: 7.996

10.  Up-regulated MicroRNA-181a induces carcinogenesis in hepatitis B virus-related hepatocellular carcinoma by targeting E2F5.

Authors:  Chengcheng Zou; Yongguo Li; Yiyi Cao; Jinnan Zhang; Jingrong Jiang; Yanrui Sheng; Sen Wang; Ailong Huang; Hua Tang
Journal:  BMC Cancer       Date:  2014-02-17       Impact factor: 4.430

View more
  22 in total

1.  MicroRNA-1179 inhibits glioblastoma cell proliferation and cell cycle progression via directly targeting E2F transcription factor 5.

Authors:  Xiupeng Xu; Ning Cai; Tongle Zhi; Zhongyuan Bao; Dong Wang; Yinlong Liu; Kuan Jiang; Liang Fan; Jing Ji; Ning Liu
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

2.  RETRACTED: Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Breast Cancer

Authors:  Cheng-Cao Sun; Shu-Jun Li; Wei Hu; Jian Zhang; Qun Zhou; Cong Liu; Lin-Lin Li; Yi-Yan Songyang; Feng Zhang; Zhen-Long Chen; Guang Li; Zhuo-Yue Bi; Yong-Yi Bi; Feng-Yun Gong; Tao Bo; Zhan-Peng Yuan; Wei-Dong Hu; Bo-Tao Zhan; Qian Zhang; Qi-Qiang He; De-Jia Li
Journal:  Mol Ther       Date:  2019-04-06       Impact factor: 11.454

3.  MicroRNA-154 as a prognostic factor in bladder cancer inhibits cellular malignancy by targeting RSF1 and RUNX2.

Authors:  Xin Zhao; Zhigang Ji; Yi Xie; Guanghua Liu; Hanzhong Li
Journal:  Oncol Rep       Date:  2017-09-25       Impact factor: 3.906

4.  MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression.

Authors:  Qinghua Cao; Fang Liu; Kaiyuan Ji; Ni Liu; Yuan He; Wenhui Zhang; Liantang Wang
Journal:  J Exp Clin Cancer Res       Date:  2017-02-13

5.  Proof-of-concept study: profile of circulating microRNAs in Bovine serum harvested during acute and persistent FMDV infection.

Authors:  Carolina Stenfeldt; Jonathan Arzt; George Smoliga; Michael LaRocco; Joseph Gutkoska; Paul Lawrence
Journal:  Virol J       Date:  2017-04-07       Impact factor: 4.099

6.  The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p.

Authors:  Mu Xu; Xiaoxiang Chen; Kang Lin; Kaixuan Zeng; Xiangxiang Liu; Bei Pan; Xueni Xu; Tao Xu; Xiuxiu Hu; Li Sun; Bangshun He; Yuqin Pan; Huiling Sun; Shukui Wang
Journal:  Mol Cancer       Date:  2018-09-28       Impact factor: 27.401

Review 7.  MicroRNAs are critical regulators of senescence and aging in mesenchymal stem cells.

Authors:  Matthew L Potter; William D Hill; Carlos M Isales; Mark W Hamrick; Sadanand Fulzele
Journal:  Bone       Date:  2020-10-03       Impact factor: 4.398

8.  In silico model for miRNA-mediated regulatory network in cancer.

Authors:  Khandakar Tanvir Ahmed; Jiao Sun; William Chen; Irene Martinez; Sze Cheng; Wencai Zhang; Jeongsik Yong; Wei Zhang
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 13.994

9.  The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1.

Authors:  Sen-Mao Li; Huan-Lei Wu; Xiao Yu; Kun Tang; Shao-Gang Wang; Zhang-Qun Ye; Jia Hu
Journal:  J Exp Clin Cancer Res       Date:  2018-09-05

10.  Prognostic Values of E2F1/2 Transcriptional Expressions in Chromophobe Renal Cell Carcinoma Patients: Evidence from Bioinformatics Analysis.

Authors:  Dingtao Hu; Nana Meng; Xiaoqi Lou; Zhen Li; Ying Teng; Bizhi Tu; Yanfeng Zou; Fang Wang
Journal:  Int J Gen Med       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.